Go or no go? Ionis, Sanofi, Regeneron and Roche await big regulatory decisions
October looks to be a big month for label expansions, with Dupixent and Hemlibra both poised to move into big new patient populations. Meanwhile Ionis is awaiting a…
Almirall spots an opportunity
The Spanish group shows again that there is a future in dermatology, but its Allergan deal really depends on the fate of one asset.
Upcoming events – Antibiotics from Insmed and Paratek face consecutive panels
Make-or-break FDA adcoms beckon for two antibiotics.
